According to the latest Future Market Insights (FMI) report, the demand for pharmaceutical caps and closures is expected to flourish at a rate of 5.8% CAGR. In 2023, the market is expected to be valued at US$ 2,541.5 million. By the end of 2033, the market is projected to attain US$ 4,469.4 million.
How are Light Weight Packaging Formats Affecting the Pharmaceutical Caps and Closures Market?
How are Investments in Product Development Influencing Growth?
| Attribute | Details |
|---|---|
| Pharmaceutical Caps and Closures Market Size (2023) | US$ 2,541.5 million |
| Pharmaceutical Caps and Closures Market Size (2033) | US$ 4,469.4 million |
| Pharmaceutical Caps and Closures Market CAGR (2023 to 2033) | 5.8% CAGR |
| Pharmaceutical Caps and Closures Market CAGR (2018 to 2022) | 5.1% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Stringent rules and regulations associated with the grade of plastics used in end-use industries, especially in the food and beverages and pharmaceuticals industries might hamper market growth.
In the United States, regulations enacted by the Food and Drug Administration (FDA) have made it compulsory to implement child-resistant closures. This is projected to create key prospects for sales in the pharmaceutical industry.
Nevertheless, small firms might find it challenging to adhere to such stringent regulations. The machinery required for ascertaining stringent guidelines is often cost-intensive, which might discourage small players. This, in turn, can adversely affect the market.
Today, consumers are searching for products that are easy to access and use, with a high preference for self-resealing offerings. These factors are creating notable opportunities for manufacturers to develop consumer-friendly products.
Increasing investments in the healthcare sector in emerging countries are anticipated to boost the demand for pharmaceutical caps & closures. Local and regional players are expanding their distribution networks and manufacturing facilities to boost their business portfolios across the globe.
Increasing government initiatives for research and development is expected to provide significant opportunities in the pharmaceutical caps & closures market.
Principal Consultant
The production of pharmaceutical caps and closures was fairly limited, until recently, owing to a lack of awareness about safety concerns. According to Future Market Insights FMI), the sales of pharmaceutical caps and closures have grown at a 5.1% CAGR between 2018 and 2022.
The market gained momentum owing to accelerating demand for easy and safe packaging, leading to many innovations in the field. The demand for child-proof packaging owing to concerns over accidental consumption is rising. This is also expected to have a positive impact on the market.
A majority of children under five years are affected by unwanted harmful drugs owing to improper closing of containers as reported by the National Health Service (NHS).
With growing economies and the expansion of health care and insurance systems, the demand for pharmaceutical products is escalating strongly. It is predicted that the global pharmaceutical industry is projected to thrive at 3.6% annually in the coming years.
The demand in the market is projected to surge due to the growing emphasis on effective packaging to reduce the spoilage of pharmaceutical products and the probability of accidents. In the United States, the spending on medicines is increasing owing to new product adoption. Medical spending in Japan exceeded US$ 85 billion in 2019. The same for China touched US$ 136 billion.
The usage of medicines has jumped by 24% in 2020 as compared to 2015. Developed economies are projected to continue to use a large volume of prescribed medicines. Emerging countries are expected to use many generics and over-the-counter alternatives. With pharmaceutical spending consistently rising in developed countries, the demand for pharmaceutical caps and closures is expected to rise.
Future Market Insights expects the global pharmaceuticals caps and closures market to rise at 5.8% CAGR between 2023 and 2033.
| Country | The United States |
|---|---|
| Market Share % (2022) | 26.5% |
In the United States, the spending on medicines has steadily increased over the years, in turn driving the adoption of new caps and closure offerings. The United States is anticipated to hold over 89% of the pharmaceutical caps and closures market in North America. Also, regulations implemented by the FDA to ascertain child-resistant closures in the pharmaceutical industry have contributed to growth prospects.
Implementation of such laws is boosting research and development among manufacturers in North America. Additionally, the increasing occurrence of chronic disorders like cardiovascular disorders, cancer, and others is projected to fuel demand for various medications. This, in turn, is projected to fuel the demand for effective packaging in the pharmaceutical sector, creating opportunities for pharmaceutical caps and closure sales.
| Country | The United Kingdom |
|---|---|
| CAGR % (2023 to 2033) | 7.3% |
The United Kingdom is projected to account for over 25% of Europe’s market through the assessment period ending in 2033. There are a few key factors speeding growth in the United Kingdom market for pharmaceutical caps and closures such as:
Recent acquisitions have been propelled by the need to enlarge portfolios for non-exclusive clean injectables in the United Kingdom market. For instance,
In January 2020, Cyrano Berry launched its advanced molding technology to create extremely lightweight components, deliver reliable performance, safeguard product integrity, offer ease of drug administration, and improve patient safety.
| Country | Germany |
|---|---|
| Value Share % (2022) | 4.8% |
Germany’s market is projected to exhibit a 6.7% CAGR throughout the forecast period. Regulatory guidelines are relatively strict in Germany. As a result, achieving approvals is hard. The EMA guideline covers the exact requests for packaging materials that are in direct contact with pharma products or drugs.
Guidelines need to be met for new registration applications. As a result of stringent guidelines, elastomeric closures are increasingly used in injectable pharmaceutical products and delivery systems to ensure component functionality and suitability of parenteral products.
Plastic packaging systems create concerns associated with potential safety effects with the production of drugs and biopharmaceuticals. As a result, stringent regulation for all types of closures in Germany is restraining the market. Despite such restraints, the market is set to continue expanding in the years to follow due to the continuously spreading pharma industry.
| Country | Japan |
|---|---|
| Market Share % (2022) | 6.4% |
Increasing expenditure on healthcare has enhanced the quality of healthcare while fortifying the demand for pharmaceutical products in countries like Japan. Japan’s market is expected to account for a significant share of the sales registered in the East Asia market in 2023.
In Japan, the total annual pharmaceutical spending equals US$ 93 billion. Moreover, the government of Japan provides for healthcare spending around 40% via national insurance schemes. Japan’s pharmaceutical sector has been forecasted to grow considerably in the coming years, paving the way for the expansion of the pharmaceutical caps and closures market.
Increasing investments in the healthcare sector are anticipated to boost the demand for pharmaceutical caps & closures. Increasing government initiatives for research and development is expected to provide significant opportunities in Argentina.
The market for pharmaceutical caps and closures in Argentina is exhibiting a 4% CAGR and is expected to account for more than 11% of Latin America’s market throughout the projection period. Encouraged by notable prospects, several market players are likely to expand their presence in the country. For Instance,
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
A relatively higher adoption rate is witnessed in child resistance closures owing to their effectiveness in preventing accidental consumption. The segment is expected to account for 61% market share in 2023.
Low costs of child resistance closures result in high revenue generation in the global pharmaceuticals caps and closures market. However, tamper-resistant products are estimated to reflect a higher rate of growth owing to concerns over counterfeiting.
| Segment | Screw Caps & Closure |
|---|---|
| Value Share % (2022) | 46.96% |
Screw caps and closures are expected to continue to dominate the market during the forecast period. According to Future Market Insights, the segment is expected to hold around 46.96% of the market share through the end of 2033.
Screw caps and closures offer various benefits to manufacturers in the supply chain and are helpful in patient compliance. Besides this, they offer help in offering long shelf life and sustainability of products.
Plastic closures are lightweight, cost-effective, and easy to manufacture which is expected to enable the plastic segment to account for over 60% of the market by the end of 2033. Lightweight packaging materials have high acceptance rates among consumers.
Lightweight closure made from resins results in low plastic usage while also complying with the recent rise in demand for environment-friendly products. The manufacturing cost is also reduced due to the usage of resin in lightweight caps. Therefore, considering both economic and social benefits, offering lightweight has become a key aspect of production. This is projected to also influence the material used for manufacturing pharmaceutical caps and closures.
Many pharmaceutical and biopharmaceutical drugs for chronic diseases are available only with prescriptions. As a result, prescribed drug closures are projected to account for a market share of 74.6% by the end of 2033.
Over-the-counter (OTC) alternatives are likely to witness increasing opportunities, especially in developing countries, owing to easy access to consumers. The trend is likely to continue in the upcoming years, fueling sales in the OTC segment.
Most pharmaceutical companies are focusing on the development of small molecule and biopharmaceutical packaging with improved compatibility with container closure designs. This segment is estimated to value US$ 2.33 billion by the end of 2033. Research into biopharmaceuticals is also projected to create important growth opportunities.
Most pharma and biotech companies are focusing on pharma products with high brand awareness which is particularly true in developed countries. Pharmaceutical and biotechnology companies are likely to account for over 55% of sales in the market in 2023.
Anticancer drugs currently lead the market in terms of therapeutic class, accounting for a share of over 20.5% in 2023. The increasing occurrence of cancer the world over is expected to fuel demand in the segment.
According to the IARC, by 2040, the world is expected to register 27.5 million new cancer cases and 17.3 million cancer deaths. According to the WHO, the chances of developing cancer before 75 years of age is about 20.2% and the risk of dying from cancer before the age of 75 years is about 10.6%.
The demand for cancer treatment medications is increasing at a significant speed, which is expected to create growth opportunities in the market. The demand for pharmaceutical caps and closures for anti-cancer drugs is forecasted to rise at a CAGR of 7.5% between 2023 and 2033.
Manufacturers in the pharmaceutical caps and closures market are primarily aiming to carry out strategic collaborations and research and development to consolidate growth in a competitive and fragmented market. For Instance,
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | US$ billion for Value |
| Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania Middle East & Africa |
| Key Countries Covered | The United States, Canada, Germany, the United Kingdom, France, Italy, Spain, Poland, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, South Africa |
| Key Segments Covered | Product Type, Functionality, Material Type, Availability, Drug Modality, Therapeutic Class, End Users, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The pharmaceutical caps and closures industry is projected to reach a valuation of US$ 4,469.4 million by 2033.
Berry Global Inc. and Amcor Plc are the top players in the pharmaceutical caps and closures industry.
The United States is projected to hold a sizeable market share over the forecast period.
The pharmaceutical caps and closures industry is projected to expand at a CAGR of 5.8%.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Billion) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Billion) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Billion) Analysis By Product type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Product type, 2023 to 2033 5.3.1. Screw Caps & Closure 5.3.2. Snap Caps & Closure 5.3.3. Push-Pull Caps & Closure 5.3.4. Stopper & Seals 5.3.5. Others 5.4. Y-o-Y Growth Trend Analysis By Product type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Product type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Functionality 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Billion) Analysis By Functionality, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Functionality, 2023 to 2033 6.3.1. Child Resistant 6.3.2. Tamper-evident 6.4. Y-o-Y Growth Trend Analysis By Functionality, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Functionality, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Material type 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Billion) Analysis By Material type, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Material type, 2023 to 2033 7.3.1. Plastic 7.3.2. Elastomer 7.3.3. Metal 7.4. Y-o-Y Growth Trend Analysis By Material type, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Material type, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Avalability 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Billion) Analysis By Avalability, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Avalability, 2023 to 2033 8.3.1. Prescription (Rx) Pharmaceuticals 8.3.2. "Over-the-Counter (OTC) Pharmaceuticals" 8.4. Y-o-Y Growth Trend Analysis By Avalability, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Avalability, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Modality 9.1. Introduction / Key Findings 9.2. Historical Market Size Value (US$ Billion) Analysis By Drug Modality, 2018 to 2022 9.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Drug Modality, 2023 to 2033 9.3.1. Small Molecule (Synthetic Drugs) 9.3.2. Biopharmaceuticals 9.4. Y-o-Y Growth Trend Analysis By Drug Modality, 2018 to 2022 9.5. Absolute $ Opportunity Analysis By Drug Modality, 2023 to 2033 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutic class 10.1. Introduction / Key Findings 10.2. Historical Market Size Value (US$ Billion) Analysis By Therapeutic class, 2018 to 2022 10.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Therapeutic class, 2023 to 2033 10.3.1. Anticancer Drugs 10.3.2. Anti-infective Drugs 10.3.3. Anti-viral Drugs 10.3.4. Anti-bacterial Drugs 10.3.5. Anti-fungal Drugs 10.3.6. Cardiovascular Drugs 10.3.7. Anti-inflammatory Drugs 10.3.8. Analgesics Drugs 10.3.9. Anti-diabetics 10.3.10. Ophthalmic Drugs 10.3.11. Neurological Drugs 10.4. Y-o-Y Growth Trend Analysis By Therapeutic class, 2018 to 2022 10.5. Absolute $ Opportunity Analysis By Therapeutic class, 2023 to 2033 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Neurological Drugs 11.1. Introduction / Key Findings 11.2. Historical Market Size Value (US$ Billion) Analysis By Neurological Drugs, 2018 to 2022 11.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Neurological Drugs, 2023 to 2033 11.3.1. Pharmaceutical & Biotechnology Companies 11.3.2. Contract Manufacturing Organizations (CMO) 11.3.3. Contract Research Organizations (CRO) 11.3.4. Academic & Research Institutes 11.4. Y-o-Y Growth Trend Analysis By Neurological Drugs, 2018 to 2022 11.5. Absolute $ Opportunity Analysis By Neurological Drugs, 2023 to 2033 12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 12.1. Introduction 12.2. Historical Market Size Value (US$ Billion) Analysis By Region, 2018 to 2022 12.3. Current Market Size Value (US$ Billion) Analysis and Forecast By Region, 2023 to 2033 12.3.1. North America 12.3.2. Latin America 12.3.3. Western Europe 12.3.4. Eastern Europe 12.3.5. South Asia and Pacific 12.3.6. East Asia 12.3.7. Middle East and Africa 12.4. Market Attractiveness Analysis By Region 13. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. The USA 13.2.1.2. Canada 13.2.2. By Product type 13.2.3. By Functionality 13.2.4. By Material type 13.2.5. By Avalability 13.2.6. By Drug Modality 13.2.7. By Therapeutic class 13.2.8. By Neurological Drugs 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Product type 13.3.3. By Functionality 13.3.4. By Material type 13.3.5. By Avalability 13.3.6. By Drug Modality 13.3.7. By Therapeutic class 13.3.8. By Neurological Drugs 13.4. Key Takeaways 14. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Brazil 14.2.1.2. Mexico 14.2.1.3. Rest of Latin America 14.2.2. By Product type 14.2.3. By Functionality 14.2.4. By Material type 14.2.5. By Avalability 14.2.6. By Drug Modality 14.2.7. By Therapeutic class 14.2.8. By Neurological Drugs 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Product type 14.3.3. By Functionality 14.3.4. By Material type 14.3.5. By Avalability 14.3.6. By Drug Modality 14.3.7. By Therapeutic class 14.3.8. By Neurological Drugs 14.4. Key Takeaways 15. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. Germany 15.2.1.2. United Kingdom 15.2.1.3. France 15.2.1.4. Spain 15.2.1.5. Italy 15.2.1.6. Rest of Western Europe 15.2.2. By Product type 15.2.3. By Functionality 15.2.4. By Material type 15.2.5. By Avalability 15.2.6. By Drug Modality 15.2.7. By Therapeutic class 15.2.8. By Neurological Drugs 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Product type 15.3.3. By Functionality 15.3.4. By Material type 15.3.5. By Avalability 15.3.6. By Drug Modality 15.3.7. By Therapeutic class 15.3.8. By Neurological Drugs 15.4. Key Takeaways 16. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. Poland 16.2.1.2. Russia 16.2.1.3. Czech Republic 16.2.1.4. Romania 16.2.1.5. Rest of Eastern Europe 16.2.2. By Product type 16.2.3. By Functionality 16.2.4. By Material type 16.2.5. By Avalability 16.2.6. By Drug Modality 16.2.7. By Therapeutic class 16.2.8. By Neurological Drugs 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Product type 16.3.3. By Functionality 16.3.4. By Material type 16.3.5. By Avalability 16.3.6. By Drug Modality 16.3.7. By Therapeutic class 16.3.8. By Neurological Drugs 16.4. Key Takeaways 17. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022 17.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033 17.2.1. By Country 17.2.1.1. India 17.2.1.2. Bangladesh 17.2.1.3. Australia 17.2.1.4. New Zealand 17.2.1.5. Rest of South Asia and Pacific 17.2.2. By Product type 17.2.3. By Functionality 17.2.4. By Material type 17.2.5. By Avalability 17.2.6. By Drug Modality 17.2.7. By Therapeutic class 17.2.8. By Neurological Drugs 17.3. Market Attractiveness Analysis 17.3.1. By Country 17.3.2. By Product type 17.3.3. By Functionality 17.3.4. By Material type 17.3.5. By Avalability 17.3.6. By Drug Modality 17.3.7. By Therapeutic class 17.3.8. By Neurological Drugs 17.4. Key Takeaways 18. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 18.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022 18.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033 18.2.1. By Country 18.2.1.1. China 18.2.1.2. Japan 18.2.1.3. South Korea 18.2.2. By Product type 18.2.3. By Functionality 18.2.4. By Material type 18.2.5. By Avalability 18.2.6. By Drug Modality 18.2.7. By Therapeutic class 18.2.8. By Neurological Drugs 18.3. Market Attractiveness Analysis 18.3.1. By Country 18.3.2. By Product type 18.3.3. By Functionality 18.3.4. By Material type 18.3.5. By Avalability 18.3.6. By Drug Modality 18.3.7. By Therapeutic class 18.3.8. By Neurological Drugs 18.4. Key Takeaways 19. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 19.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022 19.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033 19.2.1. By Country 19.2.1.1. GCC Countries 19.2.1.2. South Africa 19.2.1.3. Israel 19.2.1.4. Rest of MEA 19.2.2. By Product type 19.2.3. By Functionality 19.2.4. By Material type 19.2.5. By Avalability 19.2.6. By Drug Modality 19.2.7. By Therapeutic class 19.2.8. By Neurological Drugs 19.3. Market Attractiveness Analysis 19.3.1. By Country 19.3.2. By Product type 19.3.3. By Functionality 19.3.4. By Material type 19.3.5. By Avalability 19.3.6. By Drug Modality 19.3.7. By Therapeutic class 19.3.8. By Neurological Drugs 19.4. Key Takeaways 20. Key Countries Market Analysis 20.1. USA 20.1.1. Pricing Analysis 20.1.2. Market Share Analysis, 2022 20.1.2.1. By Product type 20.1.2.2. By Functionality 20.1.2.3. By Material type 20.1.2.4. By Avalability 20.1.2.5. By Drug Modality 20.1.2.6. By Therapeutic class 20.1.2.7. By Neurological Drugs 20.2. Canada 20.2.1. Pricing Analysis 20.2.2. Market Share Analysis, 2022 20.2.2.1. By Product type 20.2.2.2. By Functionality 20.2.2.3. By Material type 20.2.2.4. By Avalability 20.2.2.5. By Drug Modality 20.2.2.6. By Therapeutic class 20.2.2.7. By Neurological Drugs 20.3. Brazil 20.3.1. Pricing Analysis 20.3.2. Market Share Analysis, 2022 20.3.2.1. By Product type 20.3.2.2. By Functionality 20.3.2.3. By Material type 20.3.2.4. By Avalability 20.3.2.5. By Drug Modality 20.3.2.6. By Therapeutic class 20.3.2.7. By Neurological Drugs 20.4. Mexico 20.4.1. Pricing Analysis 20.4.2. Market Share Analysis, 2022 20.4.2.1. By Product type 20.4.2.2. By Functionality 20.4.2.3. By Material type 20.4.2.4. By Avalability 20.4.2.5. By Drug Modality 20.4.2.6. By Therapeutic class 20.4.2.7. By Neurological Drugs 20.5. Germany 20.5.1. Pricing Analysis 20.5.2. Market Share Analysis, 2022 20.5.2.1. By Product type 20.5.2.2. By Functionality 20.5.2.3. By Material type 20.5.2.4. By Avalability 20.5.2.5. By Drug Modality 20.5.2.6. By Therapeutic class 20.5.2.7. By Neurological Drugs 20.6. United Kingdom 20.6.1. Pricing Analysis 20.6.2. Market Share Analysis, 2022 20.6.2.1. By Product type 20.6.2.2. By Functionality 20.6.2.3. By Material type 20.6.2.4. By Avalability 20.6.2.5. By Drug Modality 20.6.2.6. By Therapeutic class 20.6.2.7. By Neurological Drugs 20.7. France 20.7.1. Pricing Analysis 20.7.2. Market Share Analysis, 2022 20.7.2.1. By Product type 20.7.2.2. By Functionality 20.7.2.3. By Material type 20.7.2.4. By Avalability 20.7.2.5. By Drug Modality 20.7.2.6. By Therapeutic class 20.7.2.7. By Neurological Drugs 20.8. Spain 20.8.1. Pricing Analysis 20.8.2. Market Share Analysis, 2022 20.8.2.1. By Product type 20.8.2.2. By Functionality 20.8.2.3. By Material type 20.8.2.4. By Avalability 20.8.2.5. By Drug Modality 20.8.2.6. By Therapeutic class 20.8.2.7. By Neurological Drugs 20.9. Italy 20.9.1. Pricing Analysis 20.9.2. Market Share Analysis, 2022 20.9.2.1. By Product type 20.9.2.2. By Functionality 20.9.2.3. By Material type 20.9.2.4. By Avalability 20.9.2.5. By Drug Modality 20.9.2.6. By Therapeutic class 20.9.2.7. By Neurological Drugs 20.10. Poland 20.10.1. Pricing Analysis 20.10.2. Market Share Analysis, 2022 20.10.2.1. By Product type 20.10.2.2. By Functionality 20.10.2.3. By Material type 20.10.2.4. By Avalability 20.10.2.5. By Drug Modality 20.10.2.6. By Therapeutic class 20.10.2.7. By Neurological Drugs 20.11. Russia 20.11.1. Pricing Analysis 20.11.2. Market Share Analysis, 2022 20.11.2.1. By Product type 20.11.2.2. By Functionality 20.11.2.3. By Material type 20.11.2.4. By Avalability 20.11.2.5. By Drug Modality 20.11.2.6. By Therapeutic class 20.11.2.7. By Neurological Drugs 20.12. Czech Republic 20.12.1. Pricing Analysis 20.12.2. Market Share Analysis, 2022 20.12.2.1. By Product type 20.12.2.2. By Functionality 20.12.2.3. By Material type 20.12.2.4. By Avalability 20.12.2.5. By Drug Modality 20.12.2.6. By Therapeutic class 20.12.2.7. By Neurological Drugs 20.13. Romania 20.13.1. Pricing Analysis 20.13.2. Market Share Analysis, 2022 20.13.2.1. By Product type 20.13.2.2. By Functionality 20.13.2.3. By Material type 20.13.2.4. By Avalability 20.13.2.5. By Drug Modality 20.13.2.6. By Therapeutic class 20.13.2.7. By Neurological Drugs 20.14. India 20.14.1. Pricing Analysis 20.14.2. Market Share Analysis, 2022 20.14.2.1. By Product type 20.14.2.2. By Functionality 20.14.2.3. By Material type 20.14.2.4. By Avalability 20.14.2.5. By Drug Modality 20.14.2.6. By Therapeutic class 20.14.2.7. By Neurological Drugs 20.15. Bangladesh 20.15.1. Pricing Analysis 20.15.2. Market Share Analysis, 2022 20.15.2.1. By Product type 20.15.2.2. By Functionality 20.15.2.3. By Material type 20.15.2.4. By Avalability 20.15.2.5. By Drug Modality 20.15.2.6. By Therapeutic class 20.15.2.7. By Neurological Drugs 20.16. Australia 20.16.1. Pricing Analysis 20.16.2. Market Share Analysis, 2022 20.16.2.1. By Product type 20.16.2.2. By Functionality 20.16.2.3. By Material type 20.16.2.4. By Avalability 20.16.2.5. By Drug Modality 20.16.2.6. By Therapeutic class 20.16.2.7. By Neurological Drugs 20.17. New Zealand 20.17.1. Pricing Analysis 20.17.2. Market Share Analysis, 2022 20.17.2.1. By Product type 20.17.2.2. By Functionality 20.17.2.3. By Material type 20.17.2.4. By Avalability 20.17.2.5. By Drug Modality 20.17.2.6. By Therapeutic class 20.17.2.7. By Neurological Drugs 20.18. China 20.18.1. Pricing Analysis 20.18.2. Market Share Analysis, 2022 20.18.2.1. By Product type 20.18.2.2. By Functionality 20.18.2.3. By Material type 20.18.2.4. By Avalability 20.18.2.5. By Drug Modality 20.18.2.6. By Therapeutic class 20.18.2.7. By Neurological Drugs 20.19. Japan 20.19.1. Pricing Analysis 20.19.2. Market Share Analysis, 2022 20.19.2.1. By Product type 20.19.2.2. By Functionality 20.19.2.3. By Material type 20.19.2.4. By Avalability 20.19.2.5. By Drug Modality 20.19.2.6. By Therapeutic class 20.19.2.7. By Neurological Drugs 20.20. South Korea 20.20.1. Pricing Analysis 20.20.2. Market Share Analysis, 2022 20.20.2.1. By Product type 20.20.2.2. By Functionality 20.20.2.3. By Material type 20.20.2.4. By Avalability 20.20.2.5. By Drug Modality 20.20.2.6. By Therapeutic class 20.20.2.7. By Neurological Drugs 20.21. GCC Countries 20.21.1. Pricing Analysis 20.21.2. Market Share Analysis, 2022 20.21.2.1. By Product type 20.21.2.2. By Functionality 20.21.2.3. By Material type 20.21.2.4. By Avalability 20.21.2.5. By Drug Modality 20.21.2.6. By Therapeutic class 20.21.2.7. By Neurological Drugs 20.22. South Africa 20.22.1. Pricing Analysis 20.22.2. Market Share Analysis, 2022 20.22.2.1. By Product type 20.22.2.2. By Functionality 20.22.2.3. By Material type 20.22.2.4. By Avalability 20.22.2.5. By Drug Modality 20.22.2.6. By Therapeutic class 20.22.2.7. By Neurological Drugs 20.23. Israel 20.23.1. Pricing Analysis 20.23.2. Market Share Analysis, 2022 20.23.2.1. By Product type 20.23.2.2. By Functionality 20.23.2.3. By Material type 20.23.2.4. By Avalability 20.23.2.5. By Drug Modality 20.23.2.6. By Therapeutic class 20.23.2.7. By Neurological Drugs 21. Market Structure Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Market Share Analysis of Top Players 21.3.1. By Regional 21.3.2. By Product type 21.3.3. By Functionality 21.3.4. By Material type 21.3.5. By Avalability 21.3.6. By Drug Modality 21.3.7. By Therapeutic class 21.3.8. By Neurological Drugs 22. Competition Analysis 22.1. Competition Deep Dive 22.1.1. Berry Global Inc 22.1.1.1. Overview 22.1.1.2. Product Portfolio 22.1.1.3. Profitability by Market Segments 22.1.1.4. Sales Footprint 22.1.1.5. Strategy Overview 22.1.1.5.1. Marketing Strategy 22.1.2. Amcor Plc 22.1.2.1. Overview 22.1.2.2. Product Portfolio 22.1.2.3. Profitability by Market Segments 22.1.2.4. Sales Footprint 22.1.2.5. Strategy Overview 22.1.2.5.1. Marketing Strategy 22.1.3. Aptar, Inc. 22.1.3.1. Overview 22.1.3.2. Product Portfolio 22.1.3.3. Profitability by Market Segments 22.1.3.4. Sales Footprint 22.1.3.5. Strategy Overview 22.1.3.5.1. Marketing Strategy 22.1.4. Closure Systems International, Inc. 22.1.4.1. Overview 22.1.4.2. Product Portfolio 22.1.4.3. Profitability by Market Segments 22.1.4.4. Sales Footprint 22.1.4.5. Strategy Overview 22.1.4.5.1. Marketing Strategy 22.1.5. O.Berk Company, LLC 22.1.5.1. Overview 22.1.5.2. Product Portfolio 22.1.5.3. Profitability by Market Segments 22.1.5.4. Sales Footprint 22.1.5.5. Strategy Overview 22.1.5.5.1. Marketing Strategy 22.1.6. Bericap GmbH and Co KG 22.1.6.1. Overview 22.1.6.2. Product Portfolio 22.1.6.3. Profitability by Market Segments 22.1.6.4. Sales Footprint 22.1.6.5. Strategy Overview 22.1.6.5.1. Marketing Strategy 22.1.7. UNITED CAPS 22.1.7.1. Overview 22.1.7.2. Product Portfolio 22.1.7.3. Profitability by Market Segments 22.1.7.4. Sales Footprint 22.1.7.5. Strategy Overview 22.1.7.5.1. Marketing Strategy 22.1.8. CL Smith Company 22.1.8.1. Overview 22.1.8.2. Product Portfolio 22.1.8.3. Profitability by Market Segments 22.1.8.4. Sales Footprint 22.1.8.5. Strategy Overview 22.1.8.5.1. Marketing Strategy 22.1.9. Georg MENSHEN GmbH & Co. KG 22.1.9.1. Overview 22.1.9.2. Product Portfolio 22.1.9.3. Profitability by Market Segments 22.1.9.4. Sales Footprint 22.1.9.5. Strategy Overview 22.1.9.5.1. Marketing Strategy 22.1.10. WestRock Company 22.1.10.1. Overview 22.1.10.2. Product Portfolio 22.1.10.3. Profitability by Market Segments 22.1.10.4. Sales Footprint 22.1.10.5. Strategy Overview 22.1.10.5.1. Marketing Strategy 22.1.11. West Pharmaceutical Services, Inc 22.1.11.1. Overview 22.1.11.2. Product Portfolio 22.1.11.3. Profitability by Market Segments 22.1.11.4. Sales Footprint 22.1.11.5. Strategy Overview 22.1.11.5.1. Marketing Strategy 22.1.12. Drug Plastics & Glass Co Inc. 22.1.12.1. Overview 22.1.12.2. Product Portfolio 22.1.12.3. Profitability by Market Segments 22.1.12.4. Sales Footprint 22.1.12.5. Strategy Overview 22.1.12.5.1. Marketing Strategy 22.1.13. Gerresheimer AG 22.1.13.1. Overview 22.1.13.2. Product Portfolio 22.1.13.3. Profitability by Market Segments 22.1.13.4. Sales Footprint 22.1.13.5. Strategy Overview 22.1.13.5.1. Marketing Strategy 22.1.14. DWK Life Sciences GmbH 22.1.14.1. Overview 22.1.14.2. Product Portfolio 22.1.14.3. Profitability by Market Segments 22.1.14.4. Sales Footprint 22.1.14.5. Strategy Overview 22.1.14.5.1. Marketing Strategy 22.1.15. Parekhplast India Limited 22.1.15.1. Overview 22.1.15.2. Product Portfolio 22.1.15.3. Profitability by Market Segments 22.1.15.4. Sales Footprint 22.1.15.5. Strategy Overview 22.1.15.5.1. Marketing Strategy 22.1.16. Parshva Exim Limited 22.1.16.1. Overview 22.1.16.2. Product Portfolio 22.1.16.3. Profitability by Market Segments 22.1.16.4. Sales Footprint 22.1.16.5. Strategy Overview 22.1.16.5.1. Marketing Strategy 23. Assumptions & Acronyms Used 24. Research Methodology
Explore Healthcare Insights
View Reports
Pharmaceutical Caps and Closures Market
